SCHEMBL24596244

SCHEMBL24596244

N#Cc1cccc(Nc2nc(C(F)(F)F)ccc2Br)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.35
GABRA1 P14867 6/20 0.34
GABRG2 P18507 6/20 0.34
GABRB3 P28472 6/20 0.34
GABRA3 P34903 5/20 0.34
GABRA5 P31644 3/20 0.34
SYK P43405 4/20 0.34
CXCR1 P25024 1/20 0.34
CXCR2 P25025 1/20 0.34
ENPP1 P22413 2/20 0.33
ENPP3 O14638 1/20 0.33
IGF1R P08069 1/20 0.33
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
TAS2R14 Q9NYV8 2/20 0.31
SLC22A12 Q96S37 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596400 0.83 IGF1R (0.42) SYKENPP1ENPP3IGF1RMEN1
SCHEMBL24596360 0.82 LMNA (0.36) SYKCXCR1CXCR2ENPP1ENPP3
SCHEMBL24596254 0.81 ENPP3 (0.35) SYKENPP1ENPP3IGF1RTAS2R14
SCHEMBL24122538 0.79 GPR119 (0.38) GPR119GABRA1GABRG2GABRB3GABRA3
SCHEMBL24596284 0.78 IGF1R (0.54) IGF1RKMT2A
SCHEMBL24122511 0.74 TSHR (0.46) GPR119IGF1RMAPTNPSR1RXFP1
SCHEMBL30319920 0.73 ALDH1A1 (0.38) GPR119GABRA1GABRG2GABRB3GABRA3
SCHEMBL24154979 0.73 ALDH1A1 (0.38) GPR119GABRA1GABRG2GABRB3GABRA3
SCHEMBL24596390 0.73 LMNA (0.45) IGF1RMEN1MAPTKMT2ATAS2R14
SCHEMBL24596297 0.73 EPHX2 (0.47) MEN1MAPTKMT2ANPSR1TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A GPR119 2771/4885GABRA1 1329/4885GABRG2 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.